Outcome of de novo Ph⁺ acute leukemias versus CML-BP. Kaplan-Meier analysis shows no difference in overall survival comparing e1a2-expressing and e13/e14a2-expressing lymphoid or biphenotypic acute leukemias, but slightly superior survival compared with CML blast phase (CML-BP) assessed from the time of transformation. For the e1a2-expressing leukemias, median overall survival (OS) was 20.3 months (range, 0.5-170.5 months), and median follow-up was 18.2 months (range, 0.5-170.5 months). For e13/e14a2 lymphoid leukemias, OS was 19.3 months (range, 7.1-61.9 months) and median follow-up was 17.3 months (range, 6.0-81.2 months).